Literature DB >> 9887158

Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer.

L C Hartmann1, D J Schaid, J E Woods, T P Crotty, J L Myers, P G Arnold, P M Petty, T A Sellers, J L Johnson, S K McDonnell, M H Frost, R B Jenkins.   

Abstract

BACKGROUND: Options for women at high risk for breast cancer include surveillance, chemoprevention, and prophylactic mastectomy. The data on the outcomes for surveillance and prophylactic mastectomy are incomplete.
METHODS: We conducted a retrospective study of all women with a family history of breast cancer who underwent bilateral prophylactic mastectomy at the Mayo Clinic between 1960 and 1993. The women were divided into two groups - high risk and moderate risk - on the basis of family history. A control study of the sisters of the high-risk probands and the Gail model were used to predict the number of breast cancers expected in these two groups in the absence of prophylactic mastectomy.
RESULTS: We identified 639 women with a family history of breast cancer who had undergone bilateral prophylactic mastectomy: 214 at high risk and 425 at moderate risk. The median length of follow-up was 14 years. The median age at prophylactic mastectomy was 42 years. According to the Gall model, 37.4 breast cancers were expected in the moderate-risk group; 4 breast cancers occurred (reduction in risk, 89.5 percent; P<0.001). We compared the numbers of breast cancers among the 214 high-risk probands with the numbers among their 403 sisters who had not undergone prophylactic mastectomy. Of these sisters, 38.7 percent (156) had been given a diagnosis of breast cancer (115 cases were diagnosed before the respective proband's prophylactic mastectomy, 38 were diagnosed afterward, and the time of the diagnosis was unknown in 3 cases). By contrast, breast cancer was diagnosed in 1.4 percent (3 of 214) of the probands. Thus, prophylactic mastectomy was associated with a reduction in the incidence of breast cancer of at least 90 percent.
CONCLUSIONS: In women with a high risk of breast cancer on the basis of family history, prophylactic mastectomy can significantly reduce the incidence of breast cancer.

Entities:  

Mesh:

Year:  1999        PMID: 9887158     DOI: 10.1056/NEJM199901143400201

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  191 in total

Review 1.  The pathology of familial breast cancer: The pre-BRCA1/BRCA2 era: historical perspectives.

Authors:  M J van de Vijver
Journal:  Breast Cancer Res       Date:  1999-10-27       Impact factor: 6.466

Review 2.  The complexities of predictive genetic testing.

Authors:  J P Evans; C Skrzynia; W Burke
Journal:  BMJ       Date:  2001-04-28

3.  The privatization of risk.

Authors:  B Rockhill
Journal:  Am J Public Health       Date:  2001-03       Impact factor: 9.308

4.  BRCA1 and BRCA2 testing: weighing the demand against the benefits.

Authors:  P Devilee
Journal:  Am J Hum Genet       Date:  1999-04       Impact factor: 11.025

Review 5.  Update in internal medicine.

Authors:  F López-Jiménez; M Brito; Y W Aude; P Scheinberg; M Kaplan; D A Dixon; N Schneiderman; J F Trejo; L H López-Salazar; E J Ramírez-Barba; R Kalil; C Ortiz; J Goyos; A Buenaño; S Kottiech; G A Lamas
Journal:  Arch Med Res       Date:  2000 Jul-Aug       Impact factor: 2.235

6.  Two challenges to the double effect doctrine: euthanasia and abortion.

Authors:  A B Shaw
Journal:  J Med Ethics       Date:  2002-04       Impact factor: 2.903

Review 7.  Breast cancer.

Authors:  Monica Morrow; William Gradishar
Journal:  BMJ       Date:  2002-02-16

8.  Trial of prophylactic mastectomy is needed.

Authors:  C Palmieri
Journal:  BMJ       Date:  1999-06-05

9.  Nipple-sparing mastectomies: Clinical outcomes from a single academic institution.

Authors:  Barbara Dull; Leah Conant; Terence Myckatyn; Marissa Tenenbaum; Amy Cyr; Julie A Margenthaler
Journal:  Mol Clin Oncol       Date:  2017-04-04

10.  American Society of Clinical Oncology policy statement: the role of the oncologist in cancer prevention and risk assessment.

Authors:  Robin T Zon; Elizabeth Goss; Victor G Vogel; Rowan T Chlebowski; Ismail Jatoi; Mark E Robson; Dana S Wollins; Judy E Garber; Powel Brown; Barnett S Kramer
Journal:  J Clin Oncol       Date:  2008-12-15       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.